Skip to main content

$0.040 -0.002 (-4.76%)

High

$0.04

Low

$0.04

Trades

45

Turnover

$43,679

Volume

1,076,056
30 June 2023 at 4:10pm
Register to track ADO and receive email alerts.

European RAT Clinical Trial Halted to Refocus Initiatives

StockBot

416,823 posts

ADO released this announcement to the ASX on 2 November 2022, 17:55. The announcement is marked as price sensitive, and is 2 page(s) in length and 128.48kb in size.

You can view all announcements from ADO and see how they appear on a price chart on the announcements page.

At the date of this announcement, ADO was 0.061% short sold according to ASIC data. It was ranked the 532nd most shorted stock on the ASX. It remains ranked 627th as of the latest reported data (11 October 2024).

Other Recent Announcements from ADO
Final Director's Interest Notice 30 June 2023, 16:51
Director Retirement - Mr Parker 27 June 2023, 16:32
Response to ASX Price Query 25 May 2023, 13:25
European RAT Clinical Trial Halted to Refocus Initiatives 2 November 2022, 17:55
AnteoTech Strengthens Management team 31 October 2022, 12:16
Quarterly Update and Appendix 4C 20 October 2022, 12:40
Investor Webinar Invitation 17 October 2022, 14:43
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track ADO and receive email alerts.